Diabetic retinopathy is the leading cause of blindness in working-age adults. The scary part? In its early stages, it has no symptoms.
By the time you notice vision problems, significant damage may have already occurred.
The good news: with proper screening and timely treatment, most vision loss from diabetic retinopathy is preventable. The 2025 ADA guidelines provide clear recommendations for protecting your vision.
Diabetic retinopathy is damage to the blood vessels in the retina caused by chronic high blood sugar:
| Stage | What Happens | Symptoms |
|---|
| Mild NPDR | Small balloon-like swelling in vessels | Usually none |
| Moderate NPDR | Vessels become blocked | Usually none |
| Severe NPDR | Many vessels blocked, retina signals for new vessels | Usually none |
| PDR | New abnormal vessels grow (neovascularization) | Floaters, vision loss |
NPDR = Non-proliferative diabetic retinopathy (early stages)
PDR = Proliferative diabetic retinopathy (advanced stage)
| Feature | Description |
|---|
| What it is | Swelling in the macula (central vision area) |
| Cause | Leaking blood vessels |
| Effect | Blurred central vision |
| Can occur at | Any stage of retinopathy |
DME is a leading cause of vision loss in people with diabetes.
| Risk Factor | Why It Increases Risk |
|---|
| Duration of diabetes | Longer exposure to high glucose |
| Poor glycemic control | High A1C damages vessels |
| High blood pressure | Additional vessel damage |
| Pregnancy | Can accelerate retinopathy |
| Kidney disease (nephropathy) | Shared microvascular damage |
| Dyslipidemia | Contributes to hard exudates |
| Sleep apnea | May worsen retinopathy |
| Anemia | May exacerbate retinal damage |
| Duration of Type 1 Diabetes | Retinopathy Prevalence |
|---|
| < 5 years | ~17% |
| 5-10 years | ~50% |
| > 10 years | ~80-90% |
| Duration of Type 2 Diabetes | Retinopathy Prevalence |
|---|
| At diagnosis | ~20-30% |
| > 10 years | ~60-80% |
| Time Since Diagnosis | Recommendation |
|---|
| Within 5 years of diagnosis | Initial dilated eye exam |
| After initial exam | Annual exams |
| After stable retinopathy | May extend to every 2 years |
| Timing | Recommendation |
|---|
| At diagnosis | Initial dilated eye exam |
| After initial exam | Annual exams |
| After stable retinopathy | May extend to every 2 years |
| Timing | Recommendation |
|---|
| Before pregnancy | Comprehensive eye exam |
| First trimester | Eye exam |
| Each trimester | Monitor if retinopathy present |
| Postpartum | Reassess within 1 year |
Note: Pregnancy can rapidly worsen pre-existing retinopathy.
| Recommendation | Timing |
|---|
| Comprehensive eye exam | Before conception |
| Counseling | Discuss risk of progression |
| Close monitoring | Throughout pregnancy |
| Feature | Description |
|---|
| Procedure | Eye drops dilate pupil, retina examined |
| Duration | 20-30 minutes for exam, vision blurry for hours |
| Gold standard | Most comprehensive method |
| Frequency | Annually (or as indicated above) |
| Feature | Description |
|---|
| Procedure | Digital photos of retina |
| Duration | 5-10 minutes |
| Sensitivity | Good for detecting most retinopathy |
| Use case | Screening in primary care settings |
| Feature | Description |
|---|
| Procedure | Light waves create cross-sectional retinal images |
| Best for | Detecting macular edema |
| Duration | 5-10 minutes |
| Use case | When DME suspected or for monitoring |
| Grade | Findings | Management |
|---|
| No apparent retinopathy | No abnormalities | Routine annual screening |
| Mild NPDR | Microaneurysms only | Annual screening |
| Moderate NPDR | Microaneurysms, blot hemorrhages, hard exudates | 6-12 month follow-up |
| Severe NPDR | >20 intraretinal hemorrhages in each quadrant, venous beading | 3-month follow-up |
| PDR | Neovascularization, vitreous/preretinal hemorrhage | Immediate referral to retina specialist |
| Category | Findings |
|---|
| No DME | No retinal thickening or hard exudates in macula |
| Mild DME | Some retinal thickening or hard exudates in macula |
| Moderate DME | Retinal thickening or hard exudates approaching fovea |
| Severe DME | Retinal thickening or hard exudates involving fovea |
| Treatment | Indication |
|---|
| Optimization | Tight glycemic control, BP control |
| Observation | Regular monitoring, no immediate treatment needed |
| Treatment | Indication |
|---|
| Anti-VEGF injections | First-line for center-involved DME |
| Focal laser | For non-center DME or adjunctive |
| Steroid implants | For pseudophakic eyes or non-responders |
Anti-VEGF agents:
- Aflibercept (Eylea)
- Bevacizumab (Avastin)
- Ranibizumab (Lucentis)
| Treatment | Indication |
|---|
| Panretinal photocoagulation (PRP) | Standard treatment for PDR |
| Anti-VEGF injections | Adjunctive to PRP, or in some cases as primary |
| Vitrectomy | For vitreous hemorrhage, tractional retinal detachment |
| Indication | Description |
|---|
| Non-clearing vitreous hemorrhage | Blood in vitreous obscuring vision |
| Tractional retinal detachment | Scar tissue pulling on retina |
| Advanced PDR | Combined with PRP in selected cases |
| Intervention | Evidence |
|---|
| Intensive glycemic control | Reduces risk of retinopathy by 34-76% |
| Early control | Greatest benefit when started early |
| DCCT/EDIC trial | Legacy effect persists for decades |
| Target | Benefit |
|---|
| <130/80 mmHg | Reduces retinopathy progression |
| ACE inhibitors/ARBs | May have specific benefits for retinopathy |
| Intervention | Evidence |
|---|
| Fenofibrate | Reduced need for laser treatment in FIELD and ACCORD trials |
| Statin therapy | May slow retinopathy progression |
| Symptom | Possible Cause | Action |
|---|
| Sudden floaters | Vitreous hemorrhage | Immediate eye exam |
| Flashes of light | Vitreous traction | Immediate eye exam |
| Curtain/veil | Retinal detachment | EMERGENCY - immediate evaluation |
| Sudden vision loss | Vitreous hemorrhage, retinal detachment | EMERGENCY - immediate evaluation |
| Gradual blurring | Macular edema | Prompt evaluation |
| Distortion | Macular edema | Prompt evaluation |
| Resource | Description |
|---|
| Low vision specialist | Can prescribe adaptive devices |
| Occupational therapy | Training for daily living adaptations |
| Support groups | Emotional and practical support |
| ADA organizations | Resources and advocacy |
| Requirement | Details |
|---|
| Visual acuity | Must meet state requirements (typically 20/40 or better) |
| Visual field | Must meet state requirements |
| Responsibility | Report vision changes to DMV as required by state |
- Annual dilated eye exams prevent most diabetes-related vision loss
- Type 1 diabetes: initial exam within 5 years of diagnosis
- Type 2 diabetes: initial exam at diagnosis
- No symptoms in early stages—don't wait for vision changes
- Glycemic control significantly reduces risk and slows progression
- Anti-VEGF injections are first-line for diabetic macular edema
- Sudden vision changes require immediate evaluation
Adults with type 1 diabetes should have an initial dilated eye exam within 5 years of diagnosis, then annually. Adults with type 2 diabetes should have an exam at diagnosis, then annually. After several stable normal exams, exams may be extended to every 2 years with provider approval.
Early stages of diabetic retinopathy can stabilize or improve with improved glycemic and blood pressure control. However, once significant damage has occurred (neovascularization, scarring), it cannot be reversed. Treatment aims to prevent progression and preserve remaining vision.
Early diabetic retinopathy typically has NO symptoms. As the disease progresses, symptoms may include floaters, blurred vision, dark or empty areas in vision, difficulty perceiving colors, or vision loss. Don't wait for symptoms—regular screening detects retinopathy before symptoms occur.
No, diabetic retinopathy does not always lead to blindness. With regular screening, timely treatment, and good risk factor control, most people with diabetic retinopathy can maintain good vision. The key is early detection through regular dilated eye exams.
Driving ability depends on visual acuity and visual field, which vary by individual and stage of retinopathy. Many people with diabetic retinopathy continue to drive safely. If vision is significantly affected, driving may need to be limited or discontinued. Follow your state's DMV requirements for vision reporting.
Sources:
- American Diabetes Association. Standards of Care in Diabetes—2025. Diabetes Care 2025; 48(Suppl 1): S153-S178 (Section 13: Retinopathy)
- American Academy of Ophthalmology. Preferred Practice Pattern Guidelines: Diabetic Retinopathy
This article is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about your health, treatment, or care. Individual circumstances vary, and what is appropriate for one person may not be appropriate for another.
If you are experiencing a medical emergency, call 911 (or your local emergency number) immediately.